Clinical Trial Update: Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating emricasan, a caspase inhibitor, for non-alcoholic steatohepatitis with fibrosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibrosis
• Liver Diseases
• Non-alcoholic Steatohepatitis

Drugs mentioned

• Emricasan (emricasan)

Snippet

Sponsor: Conatus Pharmaceuticals Inc. | Conditions: Non-alcoholic Steatohepatitis, Fibrosis | Phase 2 | Status: COMPLETED